Cardiorenal Syndrome: An In-depth Review

Introduction

Cardiorenal Syndrome (CRS) represents a complex clinical entity that underscores the intricate physiological interplay between the heart and kidneys. In recent years, the recognition of CRS has surged, owing to its significant impact on morbidity, mortality, and healthcare resource utilisation. The syndrome is not merely a coincidental co-existence of cardiac and renal dysfunction but a bidirectional phenomenon where dysfunction in one organ system precipitates or exacerbates dysfunction in the other.

Definition and Classification

Cardiorenal Syndrome is broadly defined as a pathological condition in which acute or chronic dysfunction of the heart or kidneys induces acute or chronic dysfunction in the other organ. The term encapsulates a spectrum of clinical scenarios with diverse aetiologies and presentations. In 2008, the Acute Dialysis Quality Initiative (ADQI) Workgroup proposed a widely accepted classification system that stratifies CRS into five distinct types, based on the primary and secondary organ involvement and the acuity of the dysfunction.

Types of Cardiorenal Syndrome

Type 1: Acute Cardiorenal Syndrome:

This type refers to acute worsening of cardiac function (such as acute heart failure or acute coronary syndrome) leading to acute kidney injury (AKI). It is commonly observed in hospitalised patients with acute decompensated heart failure. The pathophysiological cascade involves haemodynamic alterations, neurohormonal activation, and inflammatory responses.

Type 2: Chronic Cardiorenal Syndrome

Here, chronic abnormalities in cardiac function (e.g., chronic heart failure) lead to progressive and permanent chronic kidney disease (CKD). The syndrome is marked by long-standing neurohormonal and haemodynamic disturbances resulting in gradual nephron loss.

Type 3: Acute Renocardiac Syndrome

This type denotes acute worsening of renal function (e.g., AKI due to sepsis, nephrotoxins, or glomerulonephritis) that induces acute cardiac dysfunction, which may present as arrhythmias, heart failure, or acute coronary events.

Type 4: Chronic Renocardiac Syndrome

Chronic primary kidney disease contributes to decreased cardiac function, often manifesting as left ventricular hypertrophy, heart failure, or increased risk of cardiovascular events. The pathogenesis includes chronic volume overload, anaemia, and metabolic disturbances.

Type 5: Secondary Cardiorenal Syndrome

This encompasses systemic conditions such as sepsis, diabetes mellitus, or systemic lupus erythematosus, which simultaneously cause both cardiac and renal dysfunction through shared pathophysiological mechanisms.

Epidemiology

CRS is increasingly recognised as a major public health concern globally, with a rising incidence paralleling the growing prevalence of both heart failure and chronic kidney disease. Epidemiological data suggest that up to 40% of patients hospitalised with acute decompensated heart failure develop some degree of renal impairment. Similarly, individuals with CKD have a substantially higher risk of cardiovascular morbidity and mortality compared to those with normal renal function.

Risk factors for developing CRS include advanced age, hypertension, diabetes mellitus, atherosclerotic disease, pre-existing heart failure or CKD, and exposure to nephrotoxic agents. The syndrome is more prevalent in elderly populations, and certain ethnic groups, including South Asians, may have a heightened susceptibility due to higher rates of diabetes and hypertension.

The burden of CRS is substantial in India and other developing countries due to the dual epidemics of cardiovascular and renal diseases, compounded by limited access to early diagnosis and advanced therapies.

Pathophysiology

The pathophysiological mechanisms underlying CRS are multifaceted and incompletely understood, involving a complex interplay of haemodynamic, neurohormonal, inflammatory, and immunological factors. The following mechanisms are central to the development and progression of CRS:

Haemodynamic Alterations

Reduced cardiac output, as seen in heart failure, leads to decreased renal perfusion and activation of compensatory mechanisms such as the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS). These responses aim to maintain perfusion but ultimately contribute to increased sodium and water retention, worsening both cardiac and renal function.

Neurohormonal Activation

Activation of the RAAS and SNS results in vasoconstriction, increased afterload, and further renal hypoperfusion. Chronic neurohormonal activation also promotes myocardial and renal fibrosis, accelerating organ dysfunction.

Venous Congestion

Elevated central venous pressure due to right heart failure can impair renal perfusion and glomerular filtration rate (GFR) independently of cardiac output. Venous congestion is increasingly recognised as a crucial contributor to renal dysfunction in CRS.

Inflammatory and Oxidative Stress

Systemic inflammation and oxidative stress are prevalent in both heart failure and CKD, with cytokines such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) playing pivotal roles in promoting endothelial dysfunction and tissue injury.

Other Factors

Additional contributors include anaemia, metabolic acidosis, electrolyte disturbances, and the accumulation of uremic toxins, which collectively worsen cardiac and renal outcomes.

Clinical Features

The presentation of CRS varies depending on the primary organ involved, the acuity of dysfunction, and the underlying aetiologies. Nevertheless, certain clinical features are commonly observed:

Cardiac Signs and Symptoms:

• Dyspnoea on exertion or at rest
• Orthopnoea and paroxysmal nocturnal dyspnoea
• Peripheral oedema and ascites
• Jugular venous distension
• Fatigue and exercise intolerance
• Palpitations, chest pain (in acute coronary events)

Renal Manifestations:

• Oliguria or anuria (in acute settings)
• Progressive decline in urine output
• Azotaemia (elevated blood urea and creatinine)
• Fluid overload with pulmonary congestion
• Electrolyte abnormalities (e.g., hyperkalaemia, hyponatraemia)
• Uraemic symptoms in advanced CKD (nausea, pruritus, confusion)

Systemic Findings:

• Hypertension or hypotension
• Weight gain due to fluid retention
• Signs of systemic inflammation (fever, malaise in systemic CRS)

Diagnosis

The diagnosis of CRS requires a high index of suspicion, particularly in patients with known cardiac or renal disease who develop acute or progressive dysfunction in the other organ system. A comprehensive diagnostic approach includes clinical assessment, laboratory investigations, and imaging studies.

Clinical Assessment

• Detailed history focusing on underlying heart or kidney disease, symptoms of fluid overload, and precipitating events (e.g., infection, medication changes).
• Physical examination for signs of heart failure, volume status, and complications of renal dysfunction.

Laboratory Investigations

• Renal function tests: Serum creatinine, blood urea nitrogen (BUN), estimated GFR
• Electrolyte profile: Sodium, potassium, bicarbonate, calcium, phosphate
• Cardiac biomarkers: B-type natriuretic peptide (BNP), N-terminal pro-BNP, troponins
• Urinalysis: Proteinuria, haematuria, urinary sediment
• Other markers: C-reactive protein (CRP), complete blood count (CBC), liver function tests

Imaging Studies

• Echocardiography: Assessment of left and right ventricular function, valvular disease, pericardial effusion
• Chest radiography: Pulmonary congestion, cardiomegaly, pleural effusions
• Renal ultrasonography: Kidney size, echogenicity, evidence of obstruction or chronic changes

Additional Diagnostic Tools

• Renal biopsy: In selected cases to ascertain underlying primary renal pathology
• Cardiac MRI: For detailed assessment of myocardial structure and function
• Right heart catheterisation: For haemodynamic monitoring in refractory cases

Management

Effective management of CRS necessitates an integrated, multidisciplinary approach tailored to the individual patient’s clinical scenario. The overarching goals are to optimise cardiac and renal function, alleviate symptoms, prevent complications, and improve quality of life and survival.

General Principles

• Early identification and correction of reversible precipitants (e.g., infection, volume overload, nephrotoxic drugs)
• Close monitoring of fluid status, renal function, and electrolytes
• Individualised therapy based on CRS type and severity

Pharmacological Therapy

• Diuretics: Loop diuretics are the mainstay for managing fluid overload. Combination with thiazide diuretics may be considered in refractory cases. Monitoring for electrolyte disturbances and diuretic resistance is essential.
• RAAS Inhibitors: Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) can reduce morbidity and mortality in heart failure and CKD. Dose titration and monitoring for hyperkalaemia and worsening renal function are required.
• Beta-blockers: Beneficial in chronic heart failure but may require dose adjustments in advanced renal impairment.
• Vasodilators: Agents such as nitrates and hydralazine may be used for afterload reduction in selected cases.
• Inotropes: Short-term use in acute decompensated heart failure with hypotension and poor perfusion.
• Other Agents: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown promise in reducing progression of both heart failure and CKD.

Non-Pharmacological Interventions

• Fluid Management: Careful adjustment of fluid intake and output, with consideration of daily weights, input-output charts, and haemodynamic monitoring.
• Dietary Modifications: Sodium and fluid restriction, tailored protein intake, and avoidance of potassium-rich foods in advanced CKD.
• Renal Replacement Therapy (RRT): Indicated in refractory fluid overload, severe metabolic derangements, or uraemic complications. Modalities include intermittent haemodialysis, peritoneal dialysis, and continuous renal replacement therapy (CRRT) in critically ill patients.
• Device Therapy: Use of implantable cardioverter-defibrillators (ICDs), cardiac resynchronisation therapy (CRT), and left ventricular assist devices (LVADs) in eligible heart failure patients.
• Multidisciplinary Care: Collaboration among cardiologists, nephrologists, intensivists, and allied health professionals optimises outcomes.

Special Considerations

• Medication Adjustment: Dosing of renally excreted drugs must be modified based on estimated GFR. Avoidance of nephrotoxic agents is imperative.
• Management of Comorbidities: Optimal control of diabetes, hypertension, and anaemia is crucial in both prevention and management of CRS.

Prognosis

CRS is associated with significantly worse outcomes compared to isolated cardiac or renal dysfunction. The presence of CRS portends a higher risk of hospitalisation, prolonged length of stay, recurrent decompensation, and increased mortality. Studies indicate that even mild or transient elevations in serum creatinine during acute heart failure episodes are linked to poorer prognosis.

Prognostic factors include the severity and duration of organ dysfunction, underlying aetiology, patient age, comorbid conditions, and response to therapy. Early recognition and aggressive management can mitigate adverse outcomes, but the overall prognosis remains guarded, especially in advanced stages.

Nursing Care of Patients with Cardiorenal Syndrome

Nurses, as frontline healthcare providers, play a pivotal role in the care, monitoring, and education of patients with cardiorenal syndrome.

Effective nursing care must be tailored to address the type of CRS, the stage of organ dysfunction, and the patient’s underlying comorbidities.

Assessment and Monitoring

Comprehensive Patient Assessment

Nurses should conduct thorough assessments, including:

• Vital signs: Monitor blood pressure, heart rate, respiratory rate, oxygen saturation, and temperature.
• Fluid status: Assess for signs of volume overload (edema, jugular venous distension, crackles, weight gain) or dehydration.
• Renal function: Monitor urine output (color, volume, consistency), and look for changes such as oliguria or anuria.
• Cardiac function: Observe for symptoms of heart failure (dyspnea, orthopnea, chest pain, palpitations).
• Laboratory values: Regularly monitor serum creatinine, blood urea nitrogen (BUN), electrolytes (potassium, sodium), and cardiac biomarkers (BNP, troponin as appropriate).
• Electrocardiogram (ECG) changes: Watch for arrhythmias or ischemic changes, especially in electrolyte disturbances.
• Neurological status: Assess for confusion or changes in mental status, which may indicate uremia or hypoperfusion.

Ongoing Monitoring

Continuous monitoring is essential to detect subtle changes and prevent complications:

• Daily weights: To track fluid balance.
• Intake and output: Accurate documentation is crucial for guiding fluid therapy.
• Telemetry: For patients at risk of arrhythmias.
• Skin assessment: Monitor for breakdown due to edema or immobility.

Nursing Interventions

Fluid Management

• Fluid restriction: Often necessary to prevent volume overload; educate the patient and family on the rationale and strategies to cope with restriction.
• Diuretic therapy: Monitor for efficacy and adverse effects, such as electrolyte imbalances or worsening renal function.
• Renal replacement therapy: Coordinate care for dialysis or continuous renal replacement therapy if indicated.
• IV fluids: Administer judiciously, balancing the risk of fluid overload against hypovolemia.

Medication Management

Administer and monitor medications as prescribed, being vigilant for side effects and drug interactions:

• ACE inhibitors/ARBs: Used for both cardiac and renal protection but may cause hyperkalemia and worsen renal function.
• Beta-blockers: Monitor for hypotension and bradycardia.
• Diuretics: Monitor for electrolyte disturbances, dehydration, and ototoxicity (especially with loop diuretics).
• Inotropes and vasopressors: Monitor for arrhythmias and tissue perfusion.
• Electrolyte supplements or binders: As indicated, with careful monitoring.

Nurses should educate patients about the purpose and potential side effects of their medications, and report any adverse reactions promptly.

Electrolyte Management

Electrolyte imbalances, especially hyperkalemia and hyponatremia, are common in CRS. Nurses should:

• Monitor laboratory values closely.
• Administer replacement therapy or binders as ordered.
• Educate patients on dietary restrictions or modifications.
• Recognize and intervene in emergencies such as arrhythmias related to potassium disturbances.

Oxygenation and Perfusion

• Monitor oxygen saturation and provide supplemental oxygen as needed.
• Position the patient to maximize comfort and gas exchange (e.g., semi-Fowler’s position).
• Assess for signs of hypoperfusion, such as cool extremities, delayed capillary refill, or mottled skin.

Nutritional Support

Nutrition is critical in CRS care, as malnutrition is common due to dietary restrictions and catabolic state. Nurses should:

• Collaborate with dietitians to develop individualized meal plans that consider sodium, potassium, fluid, and protein restrictions.
• Monitor for signs of malnutrition, such as muscle wasting or weight loss.
• Educate patients and families about adhering to dietary recommendations.

Skin and Pressure Injury Prevention

Due to edema and immobility, patients are at high risk for skin breakdown:

• Reposition patients regularly.
• Use pressure-relieving devices as needed.
• Keep skin clean and dry.
• Assess skin integrity daily and document findings.

Patient Education and Support

Nurses are key educators for patients and families:

• Teach about the nature of cardiorenal syndrome, treatment goals, and self-monitoring techniques.
• Explain how to recognize and respond to warning signs, such as sudden weight gain, reduced urine output, chest pain, or shortness of breath.
• Discuss medication adherence, dietary management, and the importance of follow-up appointments.
• Provide emotional support, as patients may feel overwhelmed by the complexity and chronicity of their condition.

Multidisciplinary Collaboration

Effective care for CRS patients requires teamwork. Nurses should:

• Coordinate with physicians, nephrologists, cardiologists, dietitians, pharmacists, and social workers.
• Participate in care conferences and contribute nursing insights to optimize individualized care plans.
• Facilitate communication and continuity of care across settings (hospital, outpatient, home care).

Prevention of Complications

Proactive nursing care can help prevent or minimize CRS complications, such as:

• Acute pulmonary edema
• Hyperkalemia-induced arrhythmias
• Infections (e.g., from indwelling catheters or IV lines)
• Pressure injuries from immobility and edema
• Worsening renal or cardiac function due to medication errors or fluid mismanagement

Discharge Planning and Transitional Care

Safe transitions from hospital to home or other care facilities are crucial:

• Assess readiness for discharge by evaluating patient understanding, self-care ability, and family support.
• Arrange appropriate home services, such as visiting nurses or home dialysis if needed.
• Provide clear written and verbal instructions regarding medications, diet, fluid restrictions, and signs that warrant immediate medical attention.
• Schedule follow-up appointments and reinforce the importance of attendance.

REFERENCES

1. Dai X, Zhou B, Fan S, Xiao HB. Cardiorenal syndrome: a Bright idea with earlier roots. https://pubmed.ncbi.nlm.nih.gov/35747450/. Br J Cardiol. 2021;28(2):22. Published 2021 Apr 22.
2. Desai AS, Mehra MR. Heart Failure: Management. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson J, eds. Harrison’s Principles of Internal Medicine. 21st ed. McGraw Hill; 2022.
3. Dirkx TC, Woodell TB. Cardiorenal Syndrome. In: Papadakis MA, McPhee SJ, Rabow MW, McQuaid KR, Gandhi M, eds. Current Medical Diagnosis & Treatment 2024. McGraw Hill; 2024.
4. Fox S, Berardi C, Ho H, Maisel AS. Biomarkers in Heart Failure. In: Baliga RR, Abraham WT, eds. Color Atlas and Synopsis of Heart Failure. McGraw Hill; 2018.
5. Kousa O, Rout P, Aslam A, et al. Cardiorenal Syndrome. [Updated 2025 Jun 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542305/
6. McCallum W, Testani JM. Updates in Cardiorenal Syndrome. https://pubmed.ncbi.nlm.nih.gov/37258013/. Med Clin North Am. 2023;107(4):763-780.
7. Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. https://pubmed.ncbi.nlm.nih.gov/30852913/. Circulation. 2019;139(16):e840-e878.
8. Ricci Z, Romagnoli S, Ronco C. Cardiorenal Syndrome. https://pubmed.ncbi.nlm.nih.gov/33752859/. Crit Care Clin. 2021;37(2):335-347.

Stories are the threads that bind us; through them, we understand each other, grow, and heal.

JOHN NOORD

Connect with “Nurses Lab Editorial Team”

I hope you found this information helpful. Do you have any questions or comments? Kindly write in comments section. Subscribe the Blog with your email so you can stay updated on upcoming events and the latest articles.